Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: This study aimed to assess the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) meta-analysis.

Methods: A systematic literature search of MEDLINE, PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials was conducted from January 10, 1966 to May 20, 2022. Randomized controlled trials and observational studies comparing the CCRT alone with CCRT plus ACT were included. The literature search, quality assessment, and data extraction were conducted by two reviewers independently. The primary endpoints were 3-year rates of overall survival (OS) and progression-free survival (PFS). Complete response rate, local recurrence, distant metastasis, and adverse events were secondary outcomes. The hazard ratios (HRs) and relative risk (RR) were pooled.

Results: Nine studies with a total of 2732 patients were included in this meta-analysis, including 1411 patients in the CCRT group and 1321 in the CCRT plus ACT group. The HR for 3-year rates of OS and PFS of the CCRT group compared with the CCRT plus ACT group was 0.72 [95%confidence interval (CI) = 0.44-1.17] and 0.78 (95%CI = 0.5-1.75), respectively. No significant differences were observed between the two groups in the complete response rate (RR = 1.06, 95%CI = 0.96-1.16). However, local recurrence and distant metastasis were significantly lower in the CCRT plus ACT group than in the CCRT group (RR = 0.63, 95%CI = 0.44 -0.91 and RR = 0.64, 95%CI = 0.47-0.88). Grade 3-4 acute toxicities were more frequent in the CCRT plus ACT group (RR = 1.73, 95%CI =1.19-2.52).

Conclusion: Although associated with a decreased risk of local recurrence and distant metastasis, ACT did not significantly improve the survival rate and the complete response rate with increasing grade 3-4 acute toxicities in patients with LACC. Thus, this ACT regimen cannot be recommended for patients with LACC.

Systematic Review Registration: https://inplasy.com/inplasy-2022-9-0089/, identifier INPLASY202290089.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768423PMC
http://dx.doi.org/10.3389/fonc.2022.997030DOI Listing

Publication Analysis

Top Keywords

ccrt group
28
complete response
12
response rate
12
local recurrence
12
recurrence distant
12
distant metastasis
12
ccrt
10
concurrent chemoradiotherapy
8
adjuvant chemotherapy
8
locally advanced
8

Similar Publications

Background: The optimal radiation dose for the treatment of small cell carcinoma of the esophagus (SCEC) has not been established. This study aimed to investigate the treatment outcomes and toxicities in patients with limited-stage SCEC (LS-SCEC) treated by radiotherapy.

Methods: Patients with LS-SCEC from 14 institutions were retrospectively identified between December 2000 and October 2021.

View Article and Find Full Text PDF

Introduction: Colorectal cancer is the third most prevalent malignancy and the second leading cause of cancer mortality worldwide. Neoadjuvant concurrent chemoradiotherapy (CCRT) improves survival and increases curative surgery rates in rectal cancer. C20orf56, a long non-coding RNA (lncRNA), plays diverse roles in cancer, but its association with neoadjuvant CCRT response and prognosis in rectal cancer remains unexplored.

View Article and Find Full Text PDF

Objective: To explore novel therapeutic approaches for locally advanced cervical cancer (LACC), we evaluated the efficacy and safety of hyperthermia (HT) and/or targeted therapy combined with cisplatin-based concurrent chemoradiotherapy (CCRT).

Methods: This retrospective study analyzed 119 LACC patients (tumor diameter ≥4 cm) treated at our institution (Jan 2021-Oct 2024), stratified into: CCRT (n = 48), targeted therapy + CCRT (T-CCRT, n = 44), and HT + targeted therapy + CCRT (HT-T-CCRT, n = 27). Complete/objective response rates (CRR/ORR) at 3/12 months were assessed.

View Article and Find Full Text PDF

Objective: Limited management strategies exist for cancer therapy-induced oral mucositis (OM).

Materials And Methods: We conducted a randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of Limosilactobacillus reuteri (LR) probiotic to prevent and reduce the severity of OM in head and neck cancer patients undergoing radiotherapy (RT). Patients ≥ 21 years requiring head and neck RT of ≥ 60 Gy and those undergoing concurrent chemotherapy with RT (CCRT) with no prior OM were recruited.

View Article and Find Full Text PDF

Purpose: Concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and fluorouracil (5-FU) (i.e. TPF regimen) has yielded favourable outcomes in treating advanced external auditory canal squamous cell carcinoma (EACSCC).

View Article and Find Full Text PDF